The BD Alaris infusion set FDA alert concerns a specific group of products: Cardinal Health Presource kits that contain BD Alaris pump infusion sets affected by a BD and CareFusion 303 infusion set recall. The US Food and Drug Administration published two early alerts on 20 October 2026 describing a potentially high-risk device issue, and it says it is still reviewing the information and will update its pages as significant new information becomes available.
Key takeaways from the BD Alaris infusion set FDA alert
- The FDA Center for Devices and Radiological Health published two early alerts on 20 October 2026 about Cardinal Health Presource kits containing affected BD Alaris pump infusion sets.
- BD testing found that previously claimed infusion performance was overestimated for some sets, and in some cases performance is significantly worse, according to the FDA.
- Possible effects include under-infusion, over-infusion, delayed occlusion alarms and inaccurate bolus delivery.
- As of 19 August 2026, BD had not reported any serious injuries or deaths associated with the issue.
- The alerts cover specific infusion sets and kits; they do not say that every BD Alaris pump or infusion set is affected.
What the BD Alaris infusion set FDA alert says is wrong
According to the FDA, BD’s continued testing found that the infusion performance previously claimed for some sets was overestimated, and for some sets the performance is significantly worse. The deviations most commonly occur at programmed rates under 1 mL per hour and at bolus volumes of 5 mL or less. The agency says users may not readily detect the effects, which can include under-infusion, over-infusion, delayed occlusion alarms and inaccurate bolus doses. The BD components named as restrictive include closed male luer connectors, filters, check valves, Y-sites and microbore tubing.
The second alert describes the same sets as potentially malfunctioning in ways that cause unpredictable pump behaviour, including under-infusion, over-infusion or failure to infuse. The FDA’s pages are the primary record: FDA early alert on use instructions and FDA early alert on kit correction.
Which products are affected by the BD Alaris infusion set FDA alert
The affected products are Cardinal Health Presource kits, also called Presource packs or convenience kits, that contain BD Alaris pump infusion sets covered by the related BD infusion set recall. The text of the alerts does not list kit names or catalogue numbers; it links to a separate list of affected devices. We have not reproduced that list and urge hospitals to check the FDA page and Cardinal Health’s notice.
It is important not to over-read the alert. It concerns certain infusion sets and the kits that contain them. It does not say that the BD Alaris pump itself is defective, and it does not say that all Alaris infusion sets are affected.
Who faces the highest risk under the BD Alaris infusion set FDA alert
The FDA says that neonates, paediatric patients and critically ill patients are at higher risk, because they more often receive low-rate or low-volume infusions such as antiarrhythmics or blood-pressure support medicines. In those settings small errors in delivery can matter, and the FDA says the effects could cause serious adverse events or death. The agency also says the effects may not be readily detected.
Timeline of the BD Alaris infusion set FDA alert
- 19 August 2026: BD issues a US customer letter; its statement that no serious injuries or deaths have been reported is current as of this date.
- September 2026: Cardinal Health sends its letter to affected customers. The two FDA alerts give 23 September and 24 September respectively, so we do not state a single date.
- 5 October 2026: date listed for the BD infusion set recall notice.
- 20 October 2026: the FDA publishes the early alerts.
What the FDA and Cardinal Health recommend in the BD Alaris infusion set FDA alert
The FDA’s use-instructions alert says users should identify affected product in inventory, review BD’s pump infusion set performance disclosures, and adjust clinical use, set selection or pump use as needed. If Alaris performance is not clinically appropriate, it suggests using an alternative pump, such as the BD Alaris Syringe Module or another syringe pump. If none is available, the recalled sets may be used with caution and enhanced clinical monitoring, following the warnings BD has already communicated.
Cardinal Health’s correction recommendations, as set out in the second alert, are to locate and quarantine affected kits, alert clinicians, and apply a visible warning label to each Presource kit telling clinicians to remove and discard the recalled components. Distributors that passed kits on should notify their customers. These are FDA-reported instructions and not our advice. Clinicians should follow their own hospital protocols. Problems can be reported to the FDA’s MedWatch program.
General background: what an FDA early alert is
The FDA uses early alerts to tell the public about potentially high-risk device issues before the agency has completed its review. The status can change as the agency learns more. An early alert is not a final classification of the recall. See our medical device news for related safety coverage.
Our analysis: a narrow alert with serious potential consequences
In our assessment, the BD Alaris infusion set FDA alert is narrow in scope but significant in setting. The affected sets sit inside convenience kits, which hospitals may stock without tracking each component, and the patients most at risk are those with the least margin for error. The practical task for hospitals is to find the kits and decide how to manage use in neonatal and intensive-care settings.
We do not know how many kits are affected or how many are in use. We also make no claim about the cause beyond what BD and the FDA say.
What is not disclosed about the BD Alaris infusion set FDA alert
- The number of kits and sets affected.
- The names and catalogue numbers of the kits, which are in a linked list we did not reproduce.
- Any injuries or deaths after 19 August 2026.
- The root cause of the overestimated performance.
- The FDA’s timetable for updates.
Risks and caveats of the BD Alaris infusion set FDA alert
The FDA is still reviewing the issue and its pages may change. Our account is based on the two alerts, and we have not seen BD’s customer letters. This article is news reporting and not clinical, procurement or legal advice.
What to watch next after the BD Alaris infusion set FDA alert
- Updates to the FDA early alerts.
- Any change to BD’s reporting on injuries or deaths.
- Hospital notices on replacement sets or kit relabelling.
- Further information from BD.
FAQ
What is the BD Alaris infusion set FDA alert?
An FDA early alert, published on 20 October 2026, about Cardinal Health Presource kits that contain BD Alaris pump infusion sets affected by a recall.
Are all BD Alaris pumps affected?
The alert concerns specific infusion sets and the kits that contain them. It does not say all Alaris pumps are affected.
Have injuries been reported?
As of 19 August 2026, BD had not reported any serious injuries or deaths associated with the issue.
How we reported this: we relied on the two FDA early alerts and attributed every instruction and risk statement to them. Last updated 23 October 2026. This is news reporting and not advice.